hotspot -WSS

hotspot

author：hotspot 2025-09-27 23:32:23 - browse：45625

Anna Yeo/STAT

Recently approved gene therapies offer patients one-time, potentially curative treatments for genetic diseases such as sickle cell anemia and beta thalassemia. But “one-time” miracle solutions can often be multi-month affairs, require millions of dollars, and cause painful side effects. What if that doesn’t have to be the case?

In utero gene editing, or prenatal somatic cell genome editing, envisions treating a fetus diagnosed with a genetic disease before birth, thereby preventing that entire protocol and the onset of symptoms in the first place. It would also challenge the need for the ethically fraught enterprise of embryo editing, as the treatment would only make edits in the DNA of the individual fetus — edits which would not be passed on in a heritable way.

Watch this video to learn more about in utero gene editing, how it works, and why scientists believe it might be an advantageous approach to treating certain genetic diseases.

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： What causes rare myocarditis in young men after Covid vaccines?

WSS

In the gardens at Boston Children's Hospital, families find sanctuary

What to expect at HLTH 2023, the health care industry conference

FDA rejects Alnylam's heart disease treatment over insufficient data

What to expect at HLTH 2023, the health care industry conference

Former reverend arrested for allegedly killing 8

Colorectal cancer study finds potential in overlooked immune cell

focus

hotspot

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Senate panel puts off hardest PBM reforms for another day

Novavax promises a turnaround & Lilly roils the obesity market

Senate panel puts off hardest PBM reforms for another day

Peter Hotez and the public health issue of online harassment

The haunting brain science of long Covid

Bright Health sells Medicare Advantage business to Molina

The battle over 'scope creep' and who gets to be called 'doctor'

Moonlake's readout produced a cash windfall. Risks remain

Histogen: Failed biotech offers rare public look inside

focus

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Will the FTC rein in IQVIA's health data empire?

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

FDA authorizes Novavax’s updated Covid

Dems pitch expanding Medicare power to negotiate drug prices

New Alzheimer's drugs heat up race for early detection blood tests

entertainment

focus

knowledge

hotspot